trending Market Intelligence /marketintelligence/en/news-insights/trending/uYDbfP4hghjEYCLOL04j4w2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

InVivo Therapeutics director to resign

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates

Blog

COVID-19 Impact & Recovery: Investment Banking


InVivo Therapeutics director to resign

InVivo Therapeutics Holdings Corp. said that Jeffrey Hatfield will resign from the board and its audit and compensation committees, effective Dec. 31.

Hatfield's resignation is not due to any conflict or disagreement with the company or its board, InVivo Therapeutics said in a Dec. 10 regulatory document.

InVivo Therapeutics is a research and clinical-stage biomaterials and biotechnology company that develops scaffolding devices for spinal cord injuries.